This trial will study how well a new medication works in children with a rare nervous system disorder.
4 Primary · 9 Secondary · Reporting Duration: Baseline, Week 24, Week 48
Experimental Treatment
8 Total Participants · 3 Treatment Groups
Primary Treatment: Satralizumab · No Placebo Group · Phase 3
Age 2 - 11 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:18 - 65 | 100.0% |
Did not meet criteria | 100.0% |